Testing immune cells combined with chemotherapy for advanced bowel cancer

Plain-English translation of NCT03692429 on ClinicalTrials.gov ↗ · Source last updated November 2020 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing a new treatment called , which uses specially engineered immune cells to fight advanced colorectal cancer. The medication is given after you receive standard chemotherapy (either or ). Researchers want to find the right dose of this treatment and make sure it is safe for patients like you.

Advanced colorectal cancer that cannot be removed by surgery is very difficult to treat, and current chemotherapy alone does not work well enough for many patients. This trial exists to see if adding this new immune cell medication after chemotherapy might help patients live longer and healthier lives.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic adenocarcinoma of the colon or rectum that cannot be surgically removed
your cancer has progressed or come back after at least one previous chemotherapy treatment
you have measurable disease that can be tracked by imaging scans
you are in good overall health with an Eastern Cooperative Oncology Group performance status of 0 or 1 (able to care for yourself with minimal assistance)
your blood counts and organ function (liver, kidneys, heart, lungs) are adequate

You likely don't qualify if…

you have cancer in your brain or central nervous system
you have received any other experimental cancer treatment within 3 weeks before starting the study
you have received growth factor injections within 7 days before starting the study medication
you have previously received allogeneic stem cell transplantation, CAR T-cell therapy, or other genetically modified T-cell treatments

What participation looks like

You will first receive standard chemotherapy (either or ) as your regular cancer treatment. After that chemotherapy is complete, you will return to the study site to receive infusions of the new immune cell medication (). The study will monitor you closely to check for safety and see how well the treatment works. About 49 patients will be enrolled in this Phase 1 trial, which is still recruiting participants.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(4 sites)

United States

Moffit Cancer Center, Tampa, Florida

Belgium

Institut Jules Bordet, Brussels

UZ Antwerpen, Edegem

UZ Leuven, Leuven